Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting.

Volume: 43, Issue: 7, Pages: 364 - 370
Published: May 13, 2019
Abstract
null null Introduction and objectives null Nivolumab is an immunotherapy agent that has been an approved treatment for previously treated patients with advanced renal cell carcinoma (RCC). Experience in real-life settings, especially regarding immune-related adverse events, is scarce. We present our experience with reference to the safety of nivolumab in patients with metastatic RCC (mRCC) treated in 9 hospitals in Spain. null null null Material...
Paper Details
Title
Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting.
Published Date
May 13, 2019
Volume
43
Issue
7
Pages
364 - 370
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.